Patents Represented by Attorney Millennium Pharmaceuticals, Inc.
-
Patent number: 6897056Abstract: The invention provides isolated nucleic acids molecules, designated 32544 nucleic acid molecules, which encode novel phospholipase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32544 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32544 gene has been introduced or disrupted. The invention still further provides isolated 32544 proteins, fusion proteins, antigenic peptides and anti-32544 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: August 10, 2001Date of Patent: May 24, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel Meyers, Immaculada Silos-Santiago
-
Patent number: 6884771Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.Type: GrantFiled: August 9, 2000Date of Patent: April 26, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventors: Susan Acton, Keith E. Robison, Frank Y. Hsieh
-
Patent number: 6864078Abstract: The invention provides an isolated nucleic acid molecule, designated as a kinase nucleic acid molecule, which encodes a novel protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing kinase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. The invention still further provides isolated 14790 proteins, fusion proteins, antigenic peptides and anti-kinase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: February 29, 2000Date of Patent: March 8, 2005Assignees: Millennium Pharmaceuticals, Inc., Bayer CorporationInventors: William James Cook, Rosana Kapeller-Libermann, Helga Rubsamen-Waigmann, Frank Spaltmann
-
Patent number: 6864064Abstract: The present invention relates to a newly identified human lipase belonging to the family of mammalian lipases. The invention also relates to polynucleotides encoding the lipase. The invention further relates to methods using the lipase polypeptides and polynucleotides as a target for diagnosis and treatment in lipase-mediated or -related disorders. The invention further relates to drug-screening methods using the lipase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the lipase polypeptides and polynucleotides. The invention further relates to procedures for producing the lipase polypeptides and polynucleotides.Type: GrantFiled: May 17, 2004Date of Patent: March 8, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventor: Rosana Kapeller-Libermann
-
Patent number: 6864081Abstract: A DNA sequence encoding a human adenylyl cyclase is described. The amino acid sequence of the adenylyl cyclase is also described.Type: GrantFiled: July 24, 2002Date of Patent: March 8, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventor: James E. Tomlinson
-
Patent number: 6858418Abstract: Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 21, 2001Date of Patent: February 22, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventor: Martin R. Hodge
-
Patent number: 6852837Abstract: Novel TANGO-69-receptor polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length TANGO-69-receptor proteins, the invention further provides isolated TANGO-69-receptor fusion proteins, antigenic peptides and anti-TANGO-69-receptor antibodies. The invention also provides TANGO-69-receptor nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a TANGO-69-receptor gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: August 21, 2001Date of Patent: February 8, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventor: Samantha J. Busfield
-
Patent number: 6849437Abstract: The invention provides isolated nucleic acids molecules, designated 47153 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47153 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 47153 gene has been introduced or disrupted. The invention still further provides isolated 47153 proteins, fusion proteins, antigenic peptides and anti-47153 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 28, 2002Date of Patent: February 1, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rachel Meyers, Julie Beth Rosenfeld
-
Patent number: 6849743Abstract: The present invention is directed to an improved synthesis of clasto-lactacystin-?-lactone, and analogs thereof, that proceeds in fewer steps and in much greater overall yield than syntheses described in the prior art. The synthetic pathway relies upon a novel stereospecific synthesis of an oxazoline intermediate and a unique stereoselective addition of a formyl amide to the oxazoline. Also described are novel clasto-lactacystin-?-lactones, and analogs thereof and their use as proteasome inhibitors.Type: GrantFiled: December 18, 2003Date of Patent: February 1, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventors: François Soucy, Louis Flamondon, Mark Behnke, William Roush
-
Patent number: 6841372Abstract: A DNA sequence encoding a human adenylyl cyclase is described. The amino acid sequence of the adenylyl cyclase is also described.Type: GrantFiled: February 11, 2002Date of Patent: January 11, 2005Assignee: Millennium Pharmaceuticals, Inc.Inventors: Daniel R. Storm, Beth Hacker, James E. Tomlinson
-
Patent number: 6830914Abstract: Novel RGS polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length RGS proteins, the invention further provides isolated RGS fusion proteins, antigenic peptides, and anti-RGS antibodies. The invention also provides RGS nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an RGS gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 27, 2001Date of Patent: December 14, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Martin R. Hodge, David Yowe
-
Patent number: 6818427Abstract: The invention provides full-length, human isolated nucleic acids molecules, designated MEKK1 nucleic acid molecules, which encode a MEKK family member. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MEKK1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MEKK1 gene has been introduced or disrupted. The invention still further provides isolated MEKK1 proteins, fusion proteins, antigenic peptides and anti-MEKK1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: October 27, 2000Date of Patent: November 16, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Vito J. Palombella, Sha-Mei Liao
-
Patent number: 6797502Abstract: The present invention relates to a newly identified human lipase belonging to the family of mammalian lipases. The invention also relates to polynucleotides encoding the lipase. The invention further relates to methods using the lipase polypeptides and polynucleotides as a target for diagnosis and treatment in lipase-mediated or -related disorders. The invention further relates to drug-screening methods using the lipase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the lipase polypeptides and polynucleotides. The invention further relates to procedures for producing the lipase polypeptides and polynucleotides.Type: GrantFiled: September 26, 2001Date of Patent: September 28, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventor: Rosana Kapeller-Libermann
-
Patent number: 6787346Abstract: The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I&kgr;B&agr;, I&kgr;B&agr; kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specifically to the kinase, and hybridomas containing the antibodies. This invention further relates to bioassays using protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-&kgr;B. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase.Type: GrantFiled: January 17, 2002Date of Patent: September 7, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventor: Zhijian J. Chen
-
Patent number: 6787345Abstract: The invention provides isolated nucleic acids molecules, designated EPK-55053 nucleic acid molecules, which encode novel protein kinase polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing EPK-55053 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an EPK-55053 gene has been introduced or disrupted. The invention still further provides isolated EPK-55053 proteins, fusion proteins, antigenic peptides and anti-EPK-55053 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 15, 2001Date of Patent: September 7, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventor: Rory A. J. Curtis
-
Patent number: 6780627Abstract: The present invention relates to newly identified human sulfatases. In particular, the invention relates to sulfatase polypeptides and polynucleotides, methods of detecting the sulfatase polypeptides and polynucleotides, and methods of diagnosing and treating sulfatase-related disorders. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.Type: GrantFiled: January 31, 2000Date of Patent: August 24, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Maria Alexandra Glucksmann, Mark Williamson
-
Patent number: 6767730Abstract: A DNA sequence encoding a human type V adenylyl cyclase is described. The amino acid sequence of the adenylyl cyclase is also described. This adenylyl cyclase is expressed in heart and brain tissue.Type: GrantFiled: June 20, 2002Date of Patent: July 27, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventor: James E. Tomlinson
-
Patent number: 6767727Abstract: The present invention relates to newly identified human sulfatases. In particular, the invention relates to sulfatase polypeptides and polynucleotides, methods of detecting the sulfatase polypeptides and polynucleotides, and methods of diagnosing and treating sulfatase-related disorders. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.Type: GrantFiled: December 9, 2002Date of Patent: July 27, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Maria Alexandra Glucksmann, Mark Williamson, Fong Ying Tsai, Laura A. Rudolph-Owen
-
Patent number: 6764677Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: GrantFiled: May 24, 2000Date of Patent: July 20, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: John D. Sharp, Thomas M. Barnes
-
Patent number: 6759210Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.Type: GrantFiled: March 28, 1997Date of Patent: July 6, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Dean A. Falb, Michael A. Gimbrone, Jr.